{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T18:36:06Z","timestamp":1778351766060,"version":"3.51.4"},"reference-count":56,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chromosome region maintenance protein 1 (CRM1) mediates protein export from the nucleus and is a new target for anticancer therapeutics. Broader application of KPT-330 (selinexor), a first-in-class CRM1 inhibitor recently approved for relapsed multiple myeloma and diffuse large B-cell lymphoma, have been limited by substantial toxicity. We discovered that salicylates markedly enhance the antitumor activity of CRM1 inhibitors by extending the mechanisms of action beyond CRM1 inhibition. Using salicylates in combination enables targeting of a range of blood cancers with a much lower dose of selinexor, thereby potentially mitigating prohibitive clinical adverse effects. Choline salicylate (CS) with low-dose KPT-330 (K+CS) had potent, broad activity across high-risk hematological malignancies and solid-organ cancers ex vivo and in vivo. The K+CS combination was not toxic to nonmalignant cells as compared with malignant cells and was safe without inducing toxicity to normal organs in mice. Mechanistically, compared with KPT-330 alone, K+CS suppresses the expression of CRM1, Rad51, and thymidylate synthase proteins, leading to more efficient inhibition of CRM1-mediated nuclear export, impairment of DNA-damage repair, reduced pyrimidine synthesis, cell-cycle arrest in S-phase, and cell apoptosis. Moreover, the addition of poly (ADP-ribose) polymerase inhibitors further potentiates the K+CS antitumor effect. K+CS represents a new class of therapy for multiple types of blood cancers and will stimulate future investigations to exploit DNA-damage repair and nucleocytoplasmic transport for cancer therapy in general.<\/jats:p>","DOI":"10.1182\/blood.2020009013","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T04:57:42Z","timestamp":1604379462000},"page":"513-523","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3939-6252","authenticated-orcid":false,"given":"Jithma P.","family":"Abeykoon","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosheng","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin E.","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surendra","family":"Dasari","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-5531","authenticated-orcid":false,"given":"Jonas","family":"Paludo","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. John","family":"Weroha","sequence":"additional","affiliation":[{"name":"Department of Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunling","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jann N.","family":"Sarkaria","sequence":"additional","affiliation":[{"name":"Department of Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann C.","family":"Mladek","sequence":"additional","affiliation":[{"name":"Department of Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica L.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-4808","authenticated-orcid":false,"given":"Andrew L.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aishwarya","family":"Ravindran","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Laboratory Medicine and Pathology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca L.","family":"King","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Laboratory Medicine and Pathology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Boysen","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary J.","family":"Stenson","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan M.","family":"Carr","sequence":"additional","affiliation":[{"name":"Department of Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle K.","family":"Manske","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian R.","family":"Molina","sequence":"additional","affiliation":[{"name":"Department of Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-7314","authenticated-orcid":false,"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven I.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-3228","authenticated-orcid":false,"given":"Judy C.","family":"Boughey","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liewei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4383-270X","authenticated-orcid":false,"given":"Matthew P.","family":"Goetz","sequence":"additional","affiliation":[{"name":"Department of Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fergus J.","family":"Couch","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research,"},{"name":"Department of Laboratory Medicine and Pathology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"26","key":"2021012816244254300_B1","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.2174\/092986708786242859","article-title":"CRM1-mediated nuclear export of proteins and drug resistance in cancer","volume":"15","author":"Turner","year":"2008","journal-title":"Curr Med Chem"},{"key":"2021012816244254300_B2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40164-015-0002-5","article-title":"Selective inhibitors of nuclear export (SINE) in hematological malignancies","volume":"4","author":"Das","year":"2015","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2021012816244254300_B3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1227\/01.NEU.0000348550.47441.4B","article-title":"Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis","volume":"65","author":"Shen","year":"2009","journal-title":"Neurosurgery"},{"issue":"6","key":"2021012816244254300_B4","doi-asserted-by":"crossref","first-page":"E315","DOI":"10.25011\/cim.v32i6.10668","article-title":"Prognostic value of CRM1 in pancreas cancer","volume":"32","author":"Huang","year":"2009","journal-title":"Clin Invest Med"},{"issue":"8","key":"2021012816244254300_B5","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/cncr.23354","article-title":"Expression of the nuclear export protein chromosomal region maintenance\/exportin 1\/Xpo1 is a prognostic factor in human ovarian cancer","volume":"112","author":"Noske","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"2021012816244254300_B6","first-page":"229","article-title":"The expression of CRM1 is associated with prognosis in human osteosarcoma","volume":"21","author":"Yao","year":"2009","journal-title":"Oncol Rep"},{"issue":"5","key":"2021012816244254300_B7","first-page":"7515","article-title":"CRM1, a novel independent prognostic factor overexpressed in invasive breast carcinoma of poor prognosis","volume":"15","author":"Yue","year":"2018","journal-title":"Oncol Lett"},{"issue":"3","key":"2021012816244254300_B8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-019-0188-6","article-title":"The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells","volume":"9","author":"Abeykoon","year":"2019","journal-title":"Blood Cancer J"},{"issue":"8","key":"2021012816244254300_B9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"2021012816244254300_B10","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"issue":"24","key":"2021012816244254300_B11","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma [published correction appears in Blood. 20209;136(2):259]","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"key":"2021012816244254300_B12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2342-8-16","article-title":"Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper","volume":"8","author":"Jensen","year":"2008","journal-title":"BMC Med Imaging"},{"issue":"14","key":"2021012816244254300_B13","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1128\/MCB.25.14.5985-6004.2005","article-title":"Nucleolar sequestration of RelA (p65) regulates NF-kappaB-driven transcription and apoptosis","volume":"25","author":"Stark","year":"2005","journal-title":"Mol Cell Biol"},{"key":"2021012816244254300_B14","first-page":"234","article-title":"Choline salicylate: a new and more rapidly absorbed durg for salicylate therapy","volume":"173","author":"Wolf","year":"1960","journal-title":"Int Rec Med"},{"issue":"D1","key":"2021012816244254300_B15","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"2021012816244254300_B16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0959-440X(00)00146-9","article-title":"Caspases: key players in programmed cell death","volume":"10","author":"Gr\u00fctter","year":"2000","journal-title":"Curr Opin Struct Biol"},{"issue":"2","key":"2021012816244254300_B17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.14348\/molcells.2017.2275","article-title":"Cellular dynamics of Rad51 and Rad54 in response to postreplicative stress and DNA damage in HeLa cells","volume":"40","author":"Choi","year":"2017","journal-title":"Mol Cells"},{"issue":"10","key":"2021012816244254300_B18","doi-asserted-by":"crossref","first-page":"e47318","DOI":"10.1371\/journal.pone.0047318","article-title":"Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression","volume":"7","author":"Ligabue","year":"2012","journal-title":"PLoS One"},{"issue":"14","key":"2021012816244254300_B19","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.4161\/cc.8.14.9089","article-title":"Transcription factors LSF and E2Fs: tandem cyclists driving G0 to S?","volume":"8","author":"Hansen","year":"2009","journal-title":"Cell Cycle"},{"issue":"14","key":"2021012816244254300_B20","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1074\/jbc.272.14.9166","article-title":"Cell cycle regulation of the human polo-like kinase (PLK) promoter","volume":"272","author":"Uchiumi","year":"1997","journal-title":"J Biol Chem"},{"issue":"11","key":"2021012816244254300_B21","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1158\/1541-7786.MCR-18-0641","article-title":"Protein kinase D2 modulates cell cycle by stabilizing Aurora a kinase at centrosomes","volume":"16","author":"Roy","year":"2018","journal-title":"Mol Cancer Res"},{"issue":"2","key":"2021012816244254300_B22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2021012816244254300_B23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tibs.2010.08.004","article-title":"BUB1 and BUBR1: multifaceted kinases of the cell cycle","volume":"36","author":"Bolanos-Garcia","year":"2011","journal-title":"Trends Biochem Sci"},{"issue":"9","key":"2021012816244254300_B24","doi-asserted-by":"crossref","first-page":"e7064","DOI":"10.1371\/journal.pone.0007064","article-title":"Cell cycle-related cyclin b1 quantification","volume":"4","author":"Frisa","year":"2009","journal-title":"PLoS One"},{"issue":"7267","key":"2021012816244254300_B25","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"issue":"9","key":"2021012816244254300_B26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.molmed.2006.07.007","article-title":"DNA damage-induced cell death by apoptosis","volume":"12","author":"Roos","year":"2006","journal-title":"Trends Mol Med"},{"issue":"4","key":"2021012816244254300_B27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ajhg.2018.07.016","article-title":"A multiplex homology-directed DNA repair assay reveals the impact of more than 1,000 BRCA1 missense substitution variants on protein function","volume":"103","author":"Starita","year":"2018","journal-title":"Am J Hum Genet"},{"issue":"16","key":"2021012816244254300_B28","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"issue":"1-2","key":"2021012816244254300_B29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0027-5107(01)00115-4","article-title":"Homologous recombinational repair of DNA ensures mammalian chromosome stability","volume":"477","author":"Thompson","year":"2001","journal-title":"Mutat Res"},{"issue":"10","key":"2021012816244254300_B30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"O\u2019Neil","year":"2017","journal-title":"Nat Rev Genet"},{"issue":"26","key":"2021012816244254300_B31","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"2021012816244254300_B32","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood-2018-01-826008","article-title":"High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies","volume":"132","author":"Dreger","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2021012816244254300_B33","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/leu.2016.136","article-title":"Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies","volume":"30","author":"Hing","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"2021012816244254300_B34","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.neuropharm.2007.10.017","article-title":"The aspirin metabolite salicylate enhances neuronal excitation in rat hippocampal CA1 area through reducing GABAergic inhibition","volume":"54","author":"Gong","year":"2008","journal-title":"Neuropharmacology"},{"issue":"9","key":"2021012816244254300_B35","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/2159-8290.CD-NB2019-085","article-title":"XPO1 inhibitor approved for multiple myeloma","volume":"9","year":"2019","journal-title":"Cancer Discov"},{"issue":"2","key":"2021012816244254300_B36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/14740338.2020.1713088","article-title":"Selective inhibitors of nuclear export (SINEs) in myeloma: breakthrough or bust?","volume":"19","author":"Nishihori","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"2021012816244254300_B37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc.2015.4","article-title":"DNA repair, genome stability and cancer: a historical perspective","volume":"16","author":"Jeggo","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2021012816244254300_B38","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0022-2836(03)00313-9","article-title":"RAD51 is involved in repair of damage associated with DNA replication in mammalian cells","volume":"328","author":"Lundin","year":"2003","journal-title":"J Mol Biol"},{"issue":"24","key":"2021012816244254300_B39","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-15-2885","article-title":"XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase II\u03b1 to the nucleus","volume":"22","author":"Ranganathan","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"56","key":"2021012816244254300_B40","doi-asserted-by":"crossref","first-page":"30773","DOI":"10.18632\/oncotarget.25637","article-title":"Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents","volume":"9","author":"Kashyap","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"2021012816244254300_B41","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2012.219","article-title":"Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells","volume":"27","author":"Etchin","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2021012816244254300_B42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"2021012816244254300_B43","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","article-title":"XPO1 inhibitor selinexor overcomes intrinsic ibrutinib resistance in mantle cell lymphoma via nuclear retention of I\u03baB","volume":"17","author":"Ming","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2021012816244254300_B44","doi-asserted-by":"crossref","first-page":"14391","DOI":"10.1038\/srep14391","article-title":"Longitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor","volume":"5","author":"Marcus","year":"2015","journal-title":"Sci Rep"},{"issue":"1","key":"2021012816244254300_B45","doi-asserted-by":"crossref","first-page":"9749","DOI":"10.1038\/s41598-017-10325-x","article-title":"Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin","volume":"7","author":"Garg","year":"2017","journal-title":"Sci Rep"},{"key":"2021012816244254300_B46","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41420-018-0049-2","article-title":"KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to imatinib","volume":"4","author":"Nie","year":"2018","journal-title":"Cell Death Discov"},{"issue":"1","key":"2021012816244254300_B47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.chembiol.2014.11.015","article-title":"Identifying drug-target selectivity of small-molecule CRM1\/XPO1 inhibitors by CRISPR\/Cas9 genome editing","volume":"22","author":"Neggers","year":"2015","journal-title":"Chem Biol"},{"issue":"9","key":"2021012816244254300_B48","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1158\/0008-5472.CAN-15-1572","article-title":"CRM1 inhibition promotes cytotoxicity in Ewing sarcoma cells by repressing EWS-FLI1-dependent IGF-1 signaling","volume":"76","author":"Sun","year":"2016","journal-title":"Cancer Res"},{"key":"2021012816244254300_B49","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1186\/s12885-015-1936-z","article-title":"KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models [published correction appears in BMC Cancer. 2016;16:8]","volume":"15","author":"Gravina","year":"2015","journal-title":"BMC Cancer"},{"issue":"12","key":"2021012816244254300_B50","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","article-title":"XPO1 inhibitor selinexor overcomes intrinsic ibrutinib resistance in mantle cell lymphoma via nuclear retention of I\u03baB","volume":"17","author":"Ming","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2021012816244254300_B51","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1128\/MCB.16.12.7133","article-title":"A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53","volume":"16","author":"Lim","year":"1996","journal-title":"Mol Cell Biol"},{"issue":"13","key":"2021012816244254300_B52","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1073\/pnas.93.13.6236","article-title":"Targeted disruption of the Rad51 gene leads to lethality in embryonic mice","volume":"93","author":"Tsuzuki","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021012816244254300_B53","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fgene.2015.00096","article-title":"Regulators of homologous recombination repair as novel targets for cancer treatment","volume":"6","author":"Krajewska","year":"2015","journal-title":"Front Genet"},{"issue":"25","key":"2021012816244254300_B54","doi-asserted-by":"crossref","first-page":"14775","DOI":"10.1073\/pnas.95.25.14775","article-title":"A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides","volume":"95","author":"Agarwal","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2021012816244254300_B55","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1074\/jbc.M211078200","article-title":"Cell cycle-dependent regulation of pyrimidine biosynthesis","volume":"278","author":"Sigoillot","year":"2003","journal-title":"J Biol Chem"},{"issue":"3","key":"2021012816244254300_B56","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ccell.2019.07.007","article-title":"LMO2 confers synthetic lethality to PARP inhibition in DLBCL","volume":"36","author":"Parvin","year":"2019","journal-title":"Cancer Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/4\/513\/1798326\/bloodbld2020009013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/4\/513\/1798326\/bloodbld2020009013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T23:47:20Z","timestamp":1611877640000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/4\/513\/469829\/Salicylates-enhance-CRM1-inhibitor-antitumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,1,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020009013","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,28]]}}}